Chad M. Robins, CEO and Chairman at Adaptive Biotechnologies Corp (ADPT), sold 729,576 shares at $8.44 ($6.2M) on 2025-02-13, disclosed to the SEC on 2025-02-18.
Scheduled sale ($6.2M) by CEO and Chairman under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.44 | 100,287 | $846K | 13.7% |
| 2 | $8.44 | 100,287 | $846K | 13.7% |
| 3 | $8.46 | 158,921 | $1.3M | 21.8% |
| 4 | $8.46 | 158,921 | $1.3M | 21.8% |
| 5 | $8.50 | 211,160 | $1.8M | 29.1% |
| Total | $8.47 avg | 729,576 |
| $6.2M |
| 100% |
| Filing → |
| ADPT | SELL | 2026-03-13 | $6.2M | — | Filing → |
| ADPT | SELL | 2026-03-03 | $8.3M | — | Filing → |
| ADPT | SELL | 2026-02-04 | $2.3M | — | Filing → |